The Court held the Final Approval Hearing on February 26, 2020 at the United States District Court for the Eastern District of Pennsylvania.
On April 21, 2020, the Court entered an order approving the settlements, fees, expenses and incentive awards. The Final Approval Order and
accompanying Memorandum Opinion are available on the Court Documents page of this website.
The Settlement Administrator is continuing to process claim forms. Claimants that provided deficient claim forms and/or require additional
information to substantiate their claims will be notified in the upcoming weeks. Please note that all claims must be finalized prior to
distribution. If you have any questions about your claim or the claim process please contact the Settlement Administrator by email at info@ProvigilSettlement.com or call 1-877-241-7503.
The lawsuit asserts that Defendants Cephalon, Inc., Teva Pharmaceutical Industries, Ltd.,
Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc. (collectively, “Cephalon”), Mylan
Pharmaceuticals Inc. and Mylan, Inc. (formerly known as Mylan Laboratories, Inc.)
(collectively, “Mylan”), and Sun Pharmaceuticals Industries, Ltd., as successor in interest to
Ranbaxy Laboratories, Ltd. and Ranbaxy Pharmaceuticals, Inc., (collectively “Ranbaxy”)
violated state antitrust and consumer protection laws relating to the sale of the prescription
pharmaceutical Provigil. All Defendants have denied any wrongdoing.
A $48,000,000 Settlement has been reached between the End-Payor Class Plaintiffs
(consumers and third-party payors) and the Cephalon Defendants, a $14,377,600
Settlement with the Mylan Defendants, and a $3,500,000 Settlement with the Ranbaxy
Defendants. The three Settlements total $65,877,600.
How do I get a payment?
To be eligible to receive a payment if the Court approves the Settlements,
you must complete and submit a valid Claim Form by January 15, 2020.
No one is claiming that Provigil® or Modafinil is unsafe or ineffective.